[{"id":"9651d7d1-9259-4164-9a62-b578441ae0c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05730712","created_at":"2023-02-16T15:00:29.642Z","updated_at":"2025-02-25T12:29:24.132Z","phase":"Phase 2","brief_title":"Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT05730712","lead_sponsor":"Mayo Clinic","biomarkers":" NRG1","pipe":"","alterations":" ","tags":["NRG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • Xtandi (enzalutamide) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)"],"overall_status":"Recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 03/08/2024","start_date":" 03/08/2024","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-02-20"},{"id":"5949ed40-8066-4fa3-b731-56d11b1c4969","acronym":"MRT-2359-001","url":"https://clinicaltrials.gov/study/NCT05546268","created_at":"2022-09-19T13:55:51.266Z","updated_at":"2025-02-25T14:17:16.661Z","phase":"Phase 1/2","brief_title":"Study of Oral MRT-2359 in Selected Cancer Patients","source_id_and_acronym":"NCT05546268 - MRT-2359-001","lead_sponsor":"Monte Rosa Therapeutics, Inc","biomarkers":" MYC • MYCN","pipe":" | ","alterations":" MYCN amplification • MYC expression","tags":["MYC • MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification • MYC expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • fulvestrant • MRT-2359"],"overall_status":"Recruiting","enrollment":" Enrollment 174","initiation":"Initiation: 10/12/2022","start_date":" 10/12/2022","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2025-02-17"},{"id":"74783677-e3f5-4018-b600-ee9dd649695b","acronym":"ST101-101","url":"https://clinicaltrials.gov/study/NCT04478279","created_at":"2021-01-18T21:30:28.794Z","updated_at":"2025-02-25T14:07:48.179Z","phase":"Phase 1/2","brief_title":"A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04478279 - ST101-101","lead_sponsor":"Sapience Therapeutics","biomarkers":" BRAF","pipe":" | ","alterations":" HR positive • BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Xtandi (enzalutamide) • abiraterone acetate • lucicebtide (ST101)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 07/01/2020","start_date":" 07/01/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-17"},{"id":"b328f4e5-105e-4a5c-a45f-4777aede9baa","acronym":"","url":"https://clinicaltrials.gov/study/NCT05457257","created_at":"2022-07-13T11:56:53.469Z","updated_at":"2025-02-25T16:17:55.903Z","phase":"Phase 4","brief_title":"Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations","source_id_and_acronym":"NCT05457257","lead_sponsor":"AstraZeneca","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Xtandi (enzalutamide) • abiraterone acetate • prednisone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 07/29/2022","start_date":" 07/29/2022","primary_txt":" Primary completion: 10/22/2024","primary_completion_date":" 10/22/2024","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2025-02-07"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"d3bd037a-496e-40a7-bdf6-271632f38a73","acronym":"C4391001","url":"https://clinicaltrials.gov/study/NCT04557449","created_at":"2021-01-18T21:47:02.862Z","updated_at":"2025-02-25T16:45:10.545Z","phase":"Phase 1","brief_title":"Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors","source_id_and_acronym":"NCT04557449 - C4391001","lead_sponsor":"Pfizer","biomarkers":" CDKN2A • CCND1 • CD4","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["CDKN2A • CCND1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • fulvestrant • letrozole • atirmociclib (PF-07220060) • midazolam hydrochloride"],"overall_status":"Recruiting","enrollment":" Enrollment 337","initiation":"Initiation: 09/23/2020","start_date":" 09/23/2020","primary_txt":" Primary completion: 09/23/2026","primary_completion_date":" 09/23/2026","study_txt":" Completion: 11/23/2027","study_completion_date":" 11/23/2027","last_update_posted":"2025-02-05"},{"id":"021a5f18-f5e7-498d-a188-e4903f2c76f5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05588609","created_at":"2022-10-20T14:11:50.019Z","updated_at":"2025-02-25T16:54:29.545Z","phase":"Phase 2","brief_title":"Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers","source_id_and_acronym":"NCT05588609","lead_sponsor":"Merus N.V.","biomarkers":" NRG1","pipe":" | ","alterations":" NRG1 fusion","tags":["NRG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRG1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib) • Xtandi (enzalutamide) • abiraterone acetate • Bizengri (zenocutuzumab-zbco)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 11/17/2022","start_date":" 11/17/2022","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2025-02-04"},{"id":"58481425-6a53-4802-b306-7ed470c87380","acronym":"","url":"https://clinicaltrials.gov/study/NCT04221542","created_at":"2021-01-18T20:32:52.184Z","updated_at":"2025-02-25T16:52:48.663Z","phase":"Phase 1","brief_title":"Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT04221542","lead_sponsor":"Amgen","biomarkers":" STEAP1","pipe":"","alterations":" ","tags":["STEAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Xtandi (enzalutamide) • abiraterone acetate • xaluritamig (AMG 509)"],"overall_status":"Recruiting","enrollment":" Enrollment 470","initiation":"Initiation: 03/04/2020","start_date":" 03/04/2020","primary_txt":" Primary completion: 04/15/2026","primary_completion_date":" 04/15/2026","study_txt":" Completion: 08/17/2028","study_completion_date":" 08/17/2028","last_update_posted":"2025-02-04"},{"id":"ffa36ee9-c0da-420e-bc20-b503b2b0b217","acronym":"TBCRC 058","url":"https://clinicaltrials.gov/study/NCT06099769","created_at":"2023-10-25T19:14:04.278Z","updated_at":"2025-02-25T15:36:36.074Z","phase":"Phase 2","brief_title":"A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer","source_id_and_acronym":"NCT06099769 - TBCRC 058","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • PD-L1 • AR","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative • AR positive","tags":["HER-2 • PD-L1 • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative • AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • capecitabine • Xtandi (enzalutamide) • Halaven (eribulin mesylate) • Korlym (mifepristone) • Mifeprex (mifepristone)"],"overall_status":"Recruiting","enrollment":" Enrollment 201","initiation":"Initiation: 10/18/2023","start_date":" 10/18/2023","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2025-01-20"},{"id":"24120569-a11a-43a3-9af9-fba2afe807bb","acronym":"","url":"https://clinicaltrials.gov/study/NCT01650194","created_at":"2025-02-26T07:28:26.006Z","updated_at":"2025-02-26T07:28:26.006Z","phase":"Phase 2","brief_title":"A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients","source_id_and_acronym":"NCT01650194","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" CYP17A1","pipe":"","alterations":" ","tags":["CYP17A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • abiraterone acetate • prednisone"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 07/09/2012","start_date":" 07/09/2012","primary_txt":" Primary completion: 01/04/2018","primary_completion_date":" 01/04/2018","study_txt":" Completion: 01/04/2018","study_completion_date":" 01/04/2018","last_update_posted":"2024-12-10"},{"id":"9f5673ee-f7a4-40b1-ace8-59a97f2bd04f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01990196","created_at":"2021-01-18T09:04:40.027Z","updated_at":"2025-02-25T13:10:58.081Z","phase":"Phase 2","brief_title":"Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer","source_id_and_acronym":"NCT01990196","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" VIM • CDH2","pipe":" | ","alterations":" VIM expression","tags":["VIM • CDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VIM expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • dasatinib • Xtandi (enzalutamide) • Firmagon (degarelix)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 09/23/2014","start_date":" 09/23/2014","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2024-10-01"},{"id":"9eb44888-36d6-498e-87f2-66cdcbe3ea1e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02099864","created_at":"2021-01-17T17:57:53.255Z","updated_at":"2025-02-25T15:33:07.009Z","phase":"Phase 2","brief_title":"Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy","source_id_and_acronym":"NCT02099864","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" TP53 • PTEN • AR • RB1","pipe":" | ","alterations":" PTEN mutation • AR splice variant 7","tags":["TP53 • PTEN • AR • RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation • AR splice variant 7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 02/05/2014","start_date":" 02/05/2014","primary_txt":" Primary completion: 10/01/2019","primary_completion_date":" 10/01/2019","study_txt":" Completion: 07/08/2024","study_completion_date":" 07/08/2024","last_update_posted":"2024-09-19"},{"id":"db437829-c154-4ef1-a95d-32ea4e2d953d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02676986","created_at":"2021-01-18T13:03:06.360Z","updated_at":"2025-02-25T15:33:36.075Z","phase":"Phase 2","brief_title":"Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer","source_id_and_acronym":"NCT02676986","lead_sponsor":"Queen Mary University of London","biomarkers":" HER-2 • ER • AR","pipe":" | ","alterations":" AR positive • AR expression","tags":["HER-2 • ER • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive • AR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • exemestane"],"overall_status":"Completed","enrollment":" Enrollment 221","initiation":"Initiation: 08/10/2015","start_date":" 08/10/2015","primary_txt":" Primary completion: 12/31/2016","primary_completion_date":" 12/31/2016","study_txt":" Completion: 12/31/2016","study_completion_date":" 12/31/2016","last_update_posted":"2024-07-04"},{"id":"2af189ad-e994-4b2d-962e-d2e2497fe4a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02750358","created_at":"2021-01-18T13:28:26.255Z","updated_at":"2025-02-25T15:33:40.453Z","phase":"Phase 2","brief_title":"Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer","source_id_and_acronym":"NCT02750358","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2","pipe":" | ","alterations":" AR expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 05/19/2016","start_date":" 05/19/2016","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-06-21"},{"id":"9fe0152c-72e1-4a52-bb9d-c984450578a4","acronym":"ARCH","url":"https://clinicaltrials.gov/study/NCT05700903","created_at":"2023-01-26T15:02:58.180Z","updated_at":"2024-07-02T16:34:26.941Z","phase":"Phase 4","brief_title":"Contributions to Hypertension With Androgen Deprivation Therapy","source_id_and_acronym":"NCT05700903 - ARCH","lead_sponsor":"University of Colorado, Denver","biomarkers":" LCN2","pipe":"","alterations":" ","tags":["LCN2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • bicalutamide • goserelin acetate • flutamide • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 228","initiation":"Initiation: 09/20/2023","start_date":" 09/20/2023","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2024-06-12"},{"id":"aa92e647-2204-49a9-b0eb-03d672654c30","acronym":"","url":"https://clinicaltrials.gov/study/NCT05037500","created_at":"2021-09-08T14:53:05.286Z","updated_at":"2024-07-02T16:34:27.381Z","phase":"Phase 1","brief_title":"Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer","source_id_and_acronym":"NCT05037500","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" TP53 • RB1","pipe":"","alterations":" ","tags":["TP53 • RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/26/2022","start_date":" 01/26/2022","primary_txt":" Primary completion: 01/30/2025","primary_completion_date":" 01/30/2025","study_txt":" Completion: 01/30/2025","study_completion_date":" 01/30/2025","last_update_posted":"2024-06-11"},{"id":"5ab208a3-026d-4e92-9792-740f22b8d7f9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02955394","created_at":"2021-01-18T14:31:11.528Z","updated_at":"2024-07-02T16:34:36.780Z","phase":"Phase 2","brief_title":"Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer","source_id_and_acronym":"NCT02955394","lead_sponsor":"University of Colorado, Denver","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" AR expression","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • fulvestrant"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 09/21/2017","start_date":" 09/21/2017","primary_txt":" Primary completion: 02/17/2023","primary_completion_date":" 02/17/2023","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2024-06-10"},{"id":"0ed5b400-4576-472b-ab4d-5b13bfb5010f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03860987","created_at":"2021-01-18T19:02:51.031Z","updated_at":"2024-07-02T16:34:37.919Z","phase":"Phase 2","brief_title":"Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer","source_id_and_acronym":"NCT03860987","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • abiraterone acetate • prednisone • goserelin acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 04/30/2019","start_date":" 04/30/2019","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2024-06-05"},{"id":"d5547275-acd2-4edc-8fac-11affa680d28","acronym":"CELLO-1","url":"https://clinicaltrials.gov/study/NCT04179864","created_at":"2021-01-18T20:22:59.772Z","updated_at":"2024-07-02T16:34:59.510Z","phase":"Phase 1/2","brief_title":"A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer","source_id_and_acronym":"NCT04179864 - CELLO-1","lead_sponsor":"Epizyme, Inc.","biomarkers":" EZH2","pipe":"","alterations":" ","tags":["EZH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • abiraterone acetate • prednisone • Tazverik (tazemetostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 11/18/2019","start_date":" 11/18/2019","primary_txt":" Primary completion: 06/28/2024","primary_completion_date":" 06/28/2024","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-06-03"},{"id":"219d1e0e-b56c-4bab-85c7-f221ec0d5b47","acronym":"","url":"https://clinicaltrials.gov/study/NCT05252390","created_at":"2022-02-23T19:55:04.757Z","updated_at":"2024-07-02T16:35:00.496Z","phase":"Phase 1/2","brief_title":"NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05252390","lead_sponsor":"Nuvation Bio Inc.","biomarkers":" BRCA","pipe":" | ","alterations":" HRD • BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Xtandi (enzalutamide) • NUV-868"],"overall_status":"Recruiting","enrollment":" Enrollment 657","initiation":"Initiation: 03/29/2022","start_date":" 03/29/2022","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-05-29"},{"id":"d5620614-b21c-4e48-b7e1-c4792175d95e","acronym":"APEX-01","url":"https://clinicaltrials.gov/study/NCT04662580","created_at":"2023-11-22T19:16:10.387Z","updated_at":"2024-07-02T16:35:04.424Z","phase":"Phase 1","brief_title":"ARX517 in Subjects With Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT04662580 - APEX-01","lead_sponsor":"Ambrx, Inc.","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • JNJ-8177"],"overall_status":"Recruiting","enrollment":" Enrollment 262","initiation":"Initiation: 07/27/2021","start_date":" 07/27/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2024-05-10"},{"id":"d6f4d9db-9fa8-4c27-a1fe-5ae416df1f5d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02339168","created_at":"2021-04-26T09:52:48.407Z","updated_at":"2025-02-25T15:33:19.366Z","phase":"Phase 1","brief_title":"Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer","source_id_and_acronym":"NCT02339168","lead_sponsor":"University of California, Davis","biomarkers":" TNFRSF11A","pipe":"","alterations":" ","tags":["TNFRSF11A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • metformin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 06/22/2016","start_date":" 06/22/2016","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-05-08"},{"id":"14331834-8f2b-4486-822e-55a18617a637","acronym":"","url":"https://clinicaltrials.gov/study/NCT02007512","created_at":"2021-01-18T09:09:59.824Z","updated_at":"2024-07-02T16:35:07.270Z","phase":"Phase 2","brief_title":"Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer","source_id_and_acronym":"NCT02007512","lead_sponsor":"Pfizer","biomarkers":" HER-2 • AR","pipe":" | ","alterations":" AR expression","tags":["HER-2 • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • exemestane"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 247","initiation":"Initiation: 12/13/2013","start_date":" 12/13/2013","primary_txt":" Primary completion: 09/23/2016","primary_completion_date":" 09/23/2016","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-04-26"},{"id":"70736adb-b060-44c5-baf0-08a2f859c924","acronym":"","url":"https://clinicaltrials.gov/study/NCT04471974","created_at":"2021-01-18T21:29:11.594Z","updated_at":"2025-02-25T16:10:30.954Z","phase":"Phase 2","brief_title":"ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT04471974","lead_sponsor":"Rahul Aggarwal","biomarkers":" PD-L1 • RB1","pipe":" | ","alterations":" RB1 deletion • RB deletion","tags":["PD-L1 • RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RB1 deletion • RB deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Xtandi (enzalutamide) • ZEN-3694 • ZEN-3219"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 01/26/2021","start_date":" 01/26/2021","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2024-04-26"}]